Full-Time
Machine learning for drug discovery efficiency
$165k - $215k/yr
Senior, Expert
San Bruno, CA, USA
Onsite role expected to be in the office at least 4 days/week in South San Francisco Headquarters.
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Insitro focuses on drug discovery and development in the pharmaceutical research sector. The company utilizes machine learning and biological tools to predict which paths are likely to lead to successful medicines, aiming to minimize the costly failures often seen in drug R&D. By integrating machine learning with biology, Insitro creates predictive models that help avoid unproductive routes in the drug discovery process. Their team, made up of scientists, engineers, and drug hunters, collaborates to generate and use data to advance new medicines. Insitro primarily serves pharmaceutical companies, healthcare providers, and research institutions seeking more efficient drug development methods. The company likely generates revenue by selling predictive models and insights or through partnerships with other pharmaceutical firms to co-develop drugs. Insitro's goal is to enhance the efficiency and effectiveness of pharmaceutical R&D through data-driven approaches.
Company Size
201-500
Company Stage
Series C
Total Funding
$643M
Headquarters
San Francisco, California
Founded
2018
Help us improve and share your feedback! Did you find this helpful?
Excellent medical, dental, and vision coverage
Excellent mental health and well-being support
Open vacation policy
Access to free onsite baristas & cafe with daily lunch and breakfast
Access to free onsite fitness center
Commuter benefits
Paid parental leave
Competitive pay and 401(k) matching
Flexible work schedule (on site and remote)
insitro receives $25 million in milestone payments from Bristol Myers Squibb for the achievement of discovery milestones and the selection of first novel genetic target for ALS.
insitro receives $25 million in milestone payments from Bristol Myers Squibb for the achievement of discovery milestones and the selection of first novel genetic target for ALS.
Other competitors in the biotech space that use AI include Xaira Therapeutics, which has raised over $1 billion in funding and San Fransico-based Insitro, which has raised over $600 million in venture capital funding.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning. In this role, she will oversee those areas as well as data science and computational biology, inclusive of data modalities that span genetics, omics, imaging, clinical data, and molecular design. Dr. Fox, a professor in the Department of Statistics and Department of Computer Science at Stanford University, has made groundbreaking contributions in the application of machine learning in healthcare, with her pioneering work directly translating into patient impact. "AI leaders of Emily’s caliber who simultaneously have an understanding of biology and health are rare, and we are privileged to have recruited her to lead our AI/ML teams,” said Daphne Koller, Ph.D., co-founder and CEO. “Her groundbreaking work in machine learning, alongside her track record in translating research into impactful applications in healthcare, aligns perfectly with our mission to revolutionize drug discovery through data-driven approaches
insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company's board of directors.